Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nervgen Pharma Corp (OP:NGENF)

2.460 -0.029 (-1.17%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nervgen Pharma Corp

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
Via AB Newswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
NervGen Pharma Announces Leadership Transition
Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the... 
Via Newsfile
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer’s is highly complex and has a wide range of symptoms, including sleeplessness, wandering, agitation,... 
Via Benzinga
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX:... 
Via Newsfile
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
From NervGen Pharma Corp.
Via Business Wire
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Reports First Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the... 
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"),... 
Via Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),... 
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.